Condition: Narcolepsy Type 1 · Sponsor: Takeda
The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| Sleep Disorders Center of Alabama | Birmingham, Alabama, United States | Recruiting |
| Stanford Center for Sleep Sciences and Medicine | Redwood City, California, United States | Recruiting |
| SDS Clinical Trials, Inc. | Santa Ana, California, United States | Recruiting |
| Delta Waves LLC - Hunt - PPDS | Colorado Springs, Colorado, United States | Recruiting |
| Florida Pediatric Research Institute | Orlando, Florida, United States | Recruiting |
| Neurotrials Research | Atlanta, Georgia, United States | Recruiting |
| Georgia Neuro Center | Gainesville, Georgia, United States | Recruiting |
| Neurocare Inc | Newton, Massachusetts, United States | Recruiting |
| Henry Ford Medical Center - Columbus | Novi, Michigan, United States | Recruiting |
| Research Carolina Elite | Denver, North Carolina, United States | Recruiting |
| ARSM Research, LLC | Huntersville, North Carolina, United States | Recruiting |
| CTI Research Center | Cincinnati, Ohio, United States | Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05816382